Paclitaxel

This classification denotes a taxane compound and taxane-site binding agent with the molecular formula C47H51NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P88XT4IS4D, chemically known as 12-benzoate, 9-ester with (2r,3s)-n-benzoyl-3-phenylisoserine but generally known as paclitaxel, which bears US NIH Compound Identifier 36314. European Medicines Agency schedules Paclitaxel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09583MIG. The term PACLITAXEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules paclitaxel in its Anatomical Therapeutic Chemical (ATC) Classification. PACLITAXEL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule paclitaxel under HS 29329950 and SITC 51569. As of Q4 2014, PACLITAXEL remains the US FDA Preferred Term for this commodity. Paclitaxel bears US NLM identifiers UMLS ID C0144576 and NCI Concept Code C1411. SMILES: O1C2C(OC(=O)C)(C3C(C(O)C2)(C(=O)C(OC(=O)C)C2=C(C(OC(=O)C(O)C(NC(=O)C4CCCCC4)C4CCCCC4)CC(O)(C3OC(=O)C3CCCCC3)C2(C)C)C)C)C1.